GALT
Galectin Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$4.00-4.19%
Price as of Jul 20, 2026
GALT valuation
Galectin Therapeutics Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -2.02x
- Price / sales
- —
- Price / cash flow
- -13.13x
Enterprise value
- Enterprise value
- $387.1M
- EV / sales
- —
- EV / EBITDA
- -20.79x
- EV / EBIT
- -23.80x
- Market cap
- $263.3M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.